Clinical trials: Chronic Hepatitis D Infection
Chronic Hepatitis D
Burden of Hepatitis D Virus (HDV) Infection in Italy
The circulation of the Hepatitis D Virus (HDV) has considerably diminished in Italy, secondary to the control of the Hepatitis B Virus (HBV) with vaccination; this has led to the perception that HDV is vanishing and has reduced…
- Trial name
- HDV Describe (NCT05723068)
- Where
- 36 sites in Italy
- Volunteers
- 515 people
- Sponsor
- University of Turin, Italy
Chronic Delta Hepatitis
A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus
- Trial name
- LOWR-5 (NCT02968641)
- Testing
- Lonafarnib, Ritonavir
- Sponsor
- Eiger BioPharmaceuticals
Chronic Hepatitis Delta
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
The primary objective of this study is to evaluate the efficacy of bulevirtide administered subcutaneously (SC) for 48 weeks at a dose of 2 mg or 10 mg once daily for treatment of chronic hepatitis delta (CHD) in comparison to…
- Trial name
- NCT03852719
- Testing
- Bulevirtide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Long Term Vitamin D Therapy in HCV Treated Patients
Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects.
- Trial name
- VD-HCV (NCT01997203)
- Testing
- Vitamin D
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Dr. Nadia AbdelAaty AbdelKader
Chronic Hepatitis B, Acute Hepatitis B
Disease Loads and Status of Treatment
The aim of study is to evaluate the current prevalence of HDV infection, and comprehensively analyze the interaction between HDV and HBV infections in the era of NAs in Taiwan.
- Conditions
- Chronic Hepatitis B, Acute Hepatitis B, Hepatitis D
- Trial name
- NCT05264272
- Testing
- Prospective serological assays, Retrospective serological assays
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis C
Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3.
- Trial name
- NCT01151397
- Testing
- Peg + Vitamin D + Ribavirin, Peg + Ribavirin
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Hepatitis D, Chronic
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200 mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic…
- Trial name
- LOWR6 (NCT05229991)
- Testing
- Lonafarnib, Ritonavir
- Where
- 3 sites in Israel, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- Soroka University Medical Center
Chronic Hepatitis C
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 77% of naïve patients with genotype 1-3 Studies rarely address the issues of improving host…
- Trial name
- Addwin (NCT01439776)
- Testing
- Vit D
- Where
- 13 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- Hanyang University
Hepatitis D
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Multicenter pharmacological observational prospective, no-profit, study. This study was designed to get a "real-life" snapshot across several Italian Hepatology centers.
- Trial name
- D-SHIELD (NCT06122285)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Hepatitis Delta
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).
- Trial name
- NCT03852433
- Testing
- Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa)
- Where
- 20 sites in France, Moldova and 2 more
- Volunteers
- 175 people
- Sponsor
- Gilead Sciences
Hepatitis D, Chronic
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
- Trial name
- NCT05461170
- Testing
- VIR-2218, VIR-3434, NRTI
- Where
- 20 sites in Bulgaria, France and 7 more
- Volunteers
- 95 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Hepatitis B, Chronic Hepatitis D
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize that pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV) may be effective in the treatment of chronic hepatitis D…
- Trial name
- NCT00117533
- Testing
- pegylated IFN alfa-2b plus ribavirin
- Where
- 2 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis D
Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D
The goal of this clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016.
- Trial name
- NCT06649266
- Testing
- RBD1016
- Where
- 2 sites in Sweden
- Volunteers
- 14 people
- Sponsor
- Ribocure Pharmaceuticals AB
Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Background: Chronic hepatitis D is a liver disease caused by the hepatitis D virus (HDV). It can be severe and progressive. Most people with hepatitis D will develop scarring and damage to the liver.
- Trial name
- NCT02511431
- Testing
- Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Background: The COVID-19 global pandemic killed more than 6 million people worldwide. Several vaccines have been developed against the virus that causes this disease.
- Conditions
- Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD
- Trial name
- NCT05669677
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Compensated Liver Disease (Disorder), Hepatitis D, Chronic
Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection
Finding biomarkers for stopping bulevirtide treatment of patients with hepatitis delta
- Trial name
- BUL-STOP (NCT06603311)
- Testing
- Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection
- Where
- 5 sites in Germany, Italy
- Volunteers
- 20 people
- Sponsor
- Hannover Medical School
Chronic Hepatitis D Infection
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.
- Trial name
- NCT06907290
- Testing
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Where
- 38 sites in United States, Australia and 10 more
- Volunteers
- 150 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Hepatitis D, Chronic, Hepatitis B, Chronic
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
The objective of this study is to determine the effectiveness of peginterferon alfa-2b 1.5 mcg/kg/week administered for 52 weeks (wk) in previously untreated participants coinfected with hepatitis virus B and D.
- Trial name
- NCT00686790
- Testing
- Peginterferon alfa-2b (PegIntron, SCH 54031)
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Parathyroid Hormone, Tenofovir Disoproxil Fumarate
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF
Nucleot(s)ide is an antiviral drug that can reduce the number of viruses, reduce the risk of HCC, regress hepatic fibrosis and reduce death from Hepatitis B viral infection.
- Conditions
- Parathyroid Hormone, Tenofovir Disoproxil Fumarate, Chronic Hepatitis B Virus, Vitamin D
- Trial name
- TDF (NCT05313477)
- Testing
- Ergocalciferol Capsules, Calcium carbonate
- Where
- Thailand
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Mahidol University